These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 33171265)

  • 1. Non-mitotic functions of polo-like kinases in cancer cells.
    Raab CA; Raab M; Becker S; Strebhardt K
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present).
    Bian S; Zhang R; Nie J; Zhu M; Xie Z; Liao C; Wang Q
    Expert Opin Ther Pat; 2024 Sep; 34(9):789-806. PubMed ID: 38994687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
    Strebhardt K; Becker S; Matthess Y
    Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
    Park JE; Kim TS; Kim BY; Lee KS
    Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer.
    Kressin M; Fietz D; Becker S; Strebhardt K
    Cells; 2021 May; 10(5):. PubMed ID: 34065956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.
    Strebhardt K
    Nat Rev Drug Discov; 2010 Aug; 9(8):643-60. PubMed ID: 20671765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polo-like kinases inhibitors.
    Garuti L; Roberti M; Bottegoni G
    Curr Med Chem; 2012; 19(23):3937-48. PubMed ID: 22709006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polo-like kinases and acute leukemia.
    Goroshchuk O; Kolosenko I; Vidarsdottir L; Azimi A; Palm-Apergi C
    Oncogene; 2019 Jan; 38(1):1-16. PubMed ID: 30104712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mining Polo-Box domain of Polo-like kinase 1 as a new therapeutic target for cancer].
    Fu Z; Su M; Liu X; Chen Y
    Sheng Wu Gong Cheng Xue Bao; 2020 Nov; 36(11):2298-2312. PubMed ID: 33244925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.
    Zeng Y; Li N; Liu W; Zeng M; Cheng J; Huang J
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2447-2460. PubMed ID: 32627077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.
    Raab M; Krämer A; Hehlgans S; Sanhaji M; Kurunci-Csacsko E; Dötsch C; Bug G; Ottmann O; Becker S; Pachl F; Kuster B; Strebhardt K
    Mol Oncol; 2015 Jan; 9(1):140-54. PubMed ID: 25169932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.
    Li L; Wang X; Chen J; Ding H; Zhang Y; Hu TC; Hu LH; Jiang HL; Shen X
    Acta Pharmacol Sin; 2009 Oct; 30(10):1443-53. PubMed ID: 19801998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
    Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
    Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polo-like kinases in AML.
    Berg T; Bug G; Ottmann OG; Strebhardt K
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1069-74. PubMed ID: 22667760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus.
    Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Menendez JA
    Cell Cycle; 2011 Apr; 10(8):1295-302. PubMed ID: 21474997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of Plk3 in oncogenesis.
    Helmke C; Becker S; Strebhardt K
    Oncogene; 2016 Jan; 35(2):135-47. PubMed ID: 25915845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
    Craig SN; Baxter M; Chapagai D; Stafford JM; Nurmemmedov E; Altomare D; Wyatt MD; McInnes C
    Eur J Med Chem; 2022 Jan; 227():113926. PubMed ID: 34735919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors.
    Zhao XZ; Tsuji K; Hymel D; Burke TR
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31014020
    [TBL] [Abstract][Full Text] [Related]  

  • 20.  p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
    Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
    Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.